Akari Therapeutics (AKTX)
(Delayed Data from NSDQ)
$0.98 USD
-0.04 (-3.67%)
Updated Aug 13, 2025 03:58 PM ET
After-Market: $0.99 +0.01 (0.75%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AKTX 0.98 -0.04(-3.67%)
Will AKTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AKTX based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for AKTX
Morning Movers: Under Armour sinks following second quarter earnings
Akari Therapeutics sees cash runway into 2028
Akari Therapeutics reports Q2 EPS (86c) vs. (81c) last year
AKTX: Akari Therapeutics Discusses Progress in Cancer Research
Akari Therapeutics releases 'What This Means' segment for investors